Healthcare, Pharma & Life Sciences

Cellipont, Xiogenix Data Show 98-103% Accuracy in Automated Cell Therapy Fill-Finish

Image
Cellipont, Xiogenix Data Show 98-103% Accuracy in Automated Cell Therapy Fill-Finish

The Woodlands, Texas – September 15, 2026 -- Cellipont Bioservices and Xiogenix have published a joint white paper showing that Xiogenix's ARES X20+ automated fill-finish platform maintained formulation volume accuracy of 98.2% at small scale and 103.6% at large scale across an approximately 17-fold increase in process scale.

The paper, titled "Scaling Cell and Gene Therapy Manufacturing with Automated Formulation and Fill-Finish," details Cellipont's evaluation of the platform across small and large-scale cell therapy manufacturing workflows.

Only 7% of Health Plans Call Themselves Effective at Using SDoH Data

Image
Only 7% of Health Plans Call Themselves Effective at Using SDoH Data

Baltimore – September 15, 2026 -- Sixty percent of health plans collect social drivers of health (SDoH) screening data, yet just 7% describe their organizations as "very effective" at converting that data into action, according to new research from Sage Growth Partners.

The consultancy surveyed 50 health plan leaders for a report titled "From SDoH Data to Maternal Health Action," the third and final installment in its State of Maternal & NICU Care 2026 series. Eighty percent of respondents said they are only "somewhat confident" in their ability to use the SDoH data they already hold.

ImmunoGenesis Adds Biopharma, Ex-USGA Chief to Board Ahead of 2027 Data

Image
ImmunoGenesis Adds Biopharma, Ex-USGA Chief to Board Ahead of 2027 Data

Houston – September 15, 2026 -- ImmunoGenesis has appointed Reza Mazhari, Ph.D., and Mike Davis to its Board of Directors as the clinical-stage biotech advances its lead immunotherapy candidate toward key data readouts in mid-2027.

ImmunoGenesis has initiated a Phase 1b trial for lead asset IMGS-001

IMGS-001, a cytotoxic checkpoint inhibitor targeting PD-L1 and PD-L2, is being studied for immune-excluded tumors, a category that accounts for more than half of all cancers. James Barlow, President and CEO of ImmunoGenesis, said the new board members will help shape pipeline, partnering and fundraising strategy for the company's next growth phase.

PQM Endorses NKF Measure to Expand Annual CKD Testing

New York – September 15, 2026 -- The Partnership for Quality Measurement (PQM) has endorsed a National Kidney Foundation (NKF) quality measure that tracks annual kidney testing for adults with diabetes and/or high blood pressure, a move aimed at closing a diagnostic gap affecting an estimated 37 million U.S. adults with chronic kidney disease (CKD).

Measure tracks two annual tests for at-risk adults aged 18 to 85

The endorsed measure, Rate of Annual Kidney Health Evaluation Among Adults with Diabetes and/or Hypertension, monitors whether patients receive both an estimated glomerular filtration rate (eGFR) blood test and a urine albumin-creatinine ratio (uACR) test within a measurement year. The combination helps clinicians identify CKD and assess risk of disease progression and cardiovascular complications.

Bioness, OneStep Partner to Add Smartphone Gait Tracking to Neurorehab

Image
Bioness, OneStep Partner to Add Smartphone Gait Tracking to Neurorehab

Valencia, Calif. – September 15, 2026 -- Bioness Medical, Inc. and OneStep have struck a partnership that lets clinicians measure patient gait and mobility using only a smartphone, both in clinic and in daily life, the companies announced.

Data from 300 patients shows measurable gains in walking speed and stride length

More than 300 patients were evaluated on OneStep's gait analysis platform to gauge the immediate impact of functional electrical stimulation from Bioness' L300 Go and L300 Go Plus systems. Among adults using the L300 Go Plus, stride length increased by 5.9 cm and walking velocity rose from 0.68 to 0.74 m/s, with parallel gains in overall and symmetry-based gait scores.

Milagro Expands Autonomous Coding to 12 CSA Surgery Centers

Image
Milagro Expands Autonomous Coding to 12 CSA Surgery Centers

Austin, Texas – September 15, 2026 -- Milagro has extended its autonomous surgical coding platform to three additional ambulatory surgery centers operated by Constitution Surgery Alliance (CSA), bringing total deployment to 12 CSA facilities across New England and the Northeast.

CSA scales automated coding while keeping certified coders in the review loop

The expansion supports increasingly complex surgical coding workflows at CSA, one of the largest independent operators of outpatient surgery centers in the U.S. Sayword Hill, SVP of Revenue Cycle for CSA, said Milagro's automation is layered with the organization's existing coding review, quality assurance and auditing processes, allowing certified coding professionals to maintain oversight as automation scope grows.

EMD Serono Acquires PostEra's Oral Fertility Drug Programs

Image
EMD Serono Acquires PostEra's Oral Fertility Drug Programs

Boston – September 15, 2026 -- EMD Serono, Inc., the U.S. and Canada healthcare business of Merck KGaA, Darmstadt, Germany, has acquired two preclinical fertility drug programs from PostEra, a biotechnology company that uses artificial intelligence for small-molecule drug discovery.

EMD Serono takes over two AI-derived fertility programs from PostEra

The deal covers a class of follicle-stimulating hormone receptor (FSHR) agonists for ovarian stimulation in IVF and a separate class of luteinizing hormone/chorionic gonadotropin receptor (LHCGR) agonists targeting male infertility and ovulation triggering in IVF. Both programs were developed over the past two years using PostEra's Proton AI platform and remain in preclinical development, with safety and efficacy in humans not yet established.

HFNC Market to Hit $1.44B by 2031 as Vapotherm, Telesair Recapitalize

Image
HFNC Market to Hit $1.44B by 2031 as Vapotherm, Telesair Recapitalize

Delray Beach, Fla. – – September 15, 2026 -- The global High Flow Nasal Cannula (HFNC) market is projected to grow from USD 0.94 billion in 2026 to USD 1.44 billion by 2031, a compound annual growth rate of 8.9%, according to MarketsandMarkets.

North America leads a market shifting toward recurring consumables revenue

North America held the largest regional share of the HFNC market in 2025, supported by advanced critical-care infrastructure and established manufacturers. By product, consumables and accessories outpaced systems in market share, while adults represented the largest patient-type segment. Acute respiratory failure treatment led application demand, and hospitals remained the dominant end-user category due to intensive care unit and emergency department volumes.

Q'Apel Launches Lynx Aspiration Catheter for Stroke Thrombectomy in US

Image
Q'Apel Launches Lynx Aspiration Catheter for Stroke Thrombectomy in US

Fremont, Calif. – September 15, 2026 -- Q'Apel Medical has launched the Lynx Aspiration Catheter System in the United States, expanding its neurovascular portfolio into the aspiration category for mechanical thrombectomy, the standard of care for acute ischemic stroke caused by vessel occlusion.

Lynx becomes the second Q'Apel product built on proprietary QLCT technology

The Lynx system marks the second device to feature Q'Apel's proprietary Q'Apel Laser Cut Tube (QLCT) technology, following the company's earlier product on this engineering platform. The catheters use a bimetal shaft design with an open-spaced nitinol structure intended to balance proximal support with distal flexibility while resisting kinking during navigation through complex cerebrovascular anatomy.

EU Procurement Reform Pushes Germany to End Lowest-Price Drug Deals

Image
EU Procurement Reform Pushes Germany to End Lowest-Price Drug Deals

Berlin – September 15, 2026 -- The European Commission is redrawing public procurement rules to treat supply security as a strategic asset, pressuring Germany to overhaul how statutory health insurers award pharmaceutical rebate contracts.

Brussels Moves to Rank Quality and Resilience Above Lowest Price

The Commission's draft directive would require public tenders to be awarded based on the best price-quality ratio rather than price alone, explicitly allowing supply security and resilience to factor into contract awards. The proposal also permits splitting large contracts into smaller lots to reduce dependency on single suppliers and diversify supply chains. For strategically sensitive procurement categories, the draft opens the door to preferential treatment for European or trade-aligned suppliers.